Douglas McNeel, MD
Enriched profileProfessor in the Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin-Madison · University of Wisconsin-Madison School of Medicine and Public Health
Douglas McNeel is Professor in the Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin-Madison at University of Wisconsin-Madison School of Medicine and Public Health. OpenAlex indexes 344 publications with 7,407 citations (h-index 51); ClinicalTrials.gov lists 15 registered studies with this person as an investigator.
Data verified 16 Oct 2026
Overview
Updated 16 Oct 2026
Douglas McNeel, MD PHD, is Professor in the Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin-Madison at University of Wisconsin-Madison School of Medicine and Public Health. The public record shows 344 publications with 7,407 citations (h-index 51), centered on Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers, Prostate Cancer Treatment and Research. It also documents an investigator role on 15 registered clinical trials, industry payments reported by 2 companies, 9 NIH-funded awards (2002–2026).
- Most recent indexed publication: 2026 · Journal for immunotherapy of cancer
- Top research focus: Immunotherapy and Immune Responses
- 15 registered trials on ClinicalTrials.gov
- Open Payments reporting from 2 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 33 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 132.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 15 registered studies on ClinicalTrials.gov. The most recent:
- Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC
Sponsor: University of Wisconsin, Madison
- Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer
Sponsor: TechnoGenesys, Inc.
- Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer
Sponsor: Syntrix Biosystems, Inc.
Industry payments
Updated 16 Oct 2026
2 companies reported payments to CMS in program years 2021–2024. These are public disclosures, not judgments. The latest:
- Exelixis Inc.Program year20241 payment
- Janssen Research & Development, LLCProgram year20222 payments
- Janssen Research & Development, LLCProgram year20212 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
53.8%Gonadotropin Releasing Hormone Receptor Antagonist22.6%Orgovyx100%Part D<11 patientsCytochrome P450 17A1 Inhibitor19.4%Abiraterone Acetate100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
33.3%Corticosteroid33.3%Prednisone100%Part D<11 patientsHormonal (systemic)
12.9%l-Thyroxine12.9%Levothyroxine Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 16 Oct 2026
9 NIH research awards on record, funded 2002–2026 per NIH RePORTER. The latest:
- Project 2: Androgen deprivation as an immune modulating therapy in combination with targeted immunotherapy of prostate cancer
University of Wisconsin-Madison
FY2026$367,792P50CA269011
Congress activity
Updated 16 Oct 2026
47 congress contributions (2005–2024) across AACR, ASCO, ESMO per OpenAlex. The most recent:
- 1023P Long-term follow up of patients treated with a DNA vaccine (pTVG-HP) for PSA-recurrent prostate cancer
ESMO Congress
ESMO2024Presenting authorPoster - Immune system and intestinal microbiota determine efficacy of androgen depletion therapy against prostate cancer.
ASCO Annual Meeting
ASCO2022Co-author - Incorporation of intrapatient response heterogeneity using 18F-NaF PET/CT imaging improves outcome prediction models for metastatic prostate cancer patients.
ASCO Annual Meeting
ASCO2022Co-authorOnline-only
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Activation of tumor-specific CD8+ T cells prior to radiopharmaceutical therapy improves antitumor response.
Journal for immunotherapy of cancer
Article2026 - Phase 2 trial of pTVG-HP ± pTVG-AR DNA vaccines and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC).
Journal for immunotherapy of cancer
Clinical Trial2026 - Androgen deprivation, androgen receptor-targeted vaccination, and nivolumab in patients with high-risk localized prostate cancer.
Journal for immunotherapy of cancer
Clinical Trial2026
Most-cited works
by citation count (OpenAlex)- 01Role of B cells as antigen presenting cellsArticle346 citations2022
- 02Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell CarcinomaArticle295 citations2016
- 03
- 04
- 05
Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/douglas-mcneel-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
University of Chicago Pritzker School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.wisc.edu ↗ - PhD
Biochemistry and Molecular Biology, University of Chicago
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.wisc.edu ↗ - MS
Biochemistry and Molecular Biology, University of Chicago
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.wisc.edu ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.wisc.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.wisc.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →sitcancer.org ↗
- Member
American Association for Cancer Research
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.wisc.edu ↗ - Member
American Society of Clinical Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.wisc.edu ↗ - Member
Society for the Immunotherapy of Cancer
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.wisc.edu ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.wisc.edu ↗
- Challenge Award2014provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →med.wisc.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →med.wisc.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Toni Choueiri, MD
Dana-Farber Cancer Institute
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Fred Saad, MD
Centre hospitalier de l'Université de Montréal (CHUM)